Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 6/20 | 0.78 |
| ▸ | HTR1D | P28221 | 3/20 | 0.60 |
| ▸ | HTR1A | P08908 | 3/20 | 0.58 |
| ▸ | HTR6 | P50406 | 2/20 | 0.53 |
| ▸ | BCHE | P06276 | 5/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25029866 | 0.94 | HTR2A (0.73) | HTR2AHTR1DHTR1AHTR6BCHE | |
| SCHEMBL23805249 | 0.89 | HTR2A (0.80) | HTR2AHTR1DHTR1AHTR6BCHE | |
| SCHEMBL12558834 | 0.88 | HTR2A (1.00) | HTR2AHTR1DHTR1AHTR6HTR2C | |
| SCHEMBL29511892 | 0.88 | HTR2A (1.00) | HTR2AHTR1DHTR1AHTR6HTR2C | |
| SCHEMBL23805214 | 0.86 | HTR2A (0.79) | HTR2AHTR1DHTR1AHTR6BCHE | |
| SCHEMBL23723405 | 0.85 | HTR2A (0.84) | HTR2AHTR1DHTR1AHTR6HTR2C | |
| SCHEMBL4206922 | 0.85 | HTR2A (0.77) | HTR2AHTR1DHTR1AHTR6HTR2C | |
| SCHEMBL23805277 | 0.84 | HTR2A (0.79) | HTR2AHTR1DHTR1AHTR6HTR2C | |
| Hydrochloric Acid SCHEMBL31390111 | 0.83 | HTR2A (0.77) | HTR2AHTR1DHTR1AHTR6HTR2C | |
| SCHEMBL4225704 | 0.82 | HTR6 (0.75) | HTR2AHTR1DHTR1AHTR6HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230140635-A1 | 3-(2-(Aminoethyl)-Indol-4-ol Derivatives, Methods of Preparation Thereof, and the Use as 5-HT2 Receptor Modulators | BRIGHT MINDS BIOSCIENCES INC. (CA) | 2023-05-04 | — | — | US | disclosed |
| US-20230140635-A1 | 3-(2-(Aminoethyl)-Indol-4-ol Derivatives, Methods of Preparation Thereof, and the Use as 5-HT2 Receptor Modulators | BRIGHT MINDS BIOSCIENCES INC. (CA) | 2023-05-04 | — | — | US | disclosed |
| US-20230140635-A1 | 3-(2-(Aminoethyl)-Indol-4-ol Derivatives, Methods of Preparation Thereof, and the Use as 5-HT2 Receptor Modulators | BRIGHT MINDS BIOSCIENCES INC. (CA) | 2023-05-04 | — | — | US | disclosed |
| EP-4118071-A1 | 3-(2-(AMINOETHYL)-INDOL-4-OL DERIVATIVES, METHODS OF PREPARATION THEREOF, AND THE USE AS 5-HT2 RECEPTOR MODULATORS | Bright Minds Biosciences Inc. (CA) | 2023-01-18 | — | — | EP | disclosed |
| WO-2021179091-A1 | 3-(2-(AMINOETHYL)-INDOL-4-OL DERIVATIVES, METHODS OF PREPARATION THEREOF, AND THE USE AS 5-HT2 RECEPTOR MODULATORS | BRIGHT MINDS BIOSCIENCES INC. (CA) | 2021-09-16 | — | — | WO | disclosed |
| WO-2021179091-A1 | 3-(2-(AMINOETHYL)-INDOL-4-OL DERIVATIVES, METHODS OF PREPARATION THEREOF, AND THE USE AS 5-HT2 RECEPTOR MODULATORS | BRIGHT MINDS BIOSCIENCES INC. (CA) | 2021-09-16 | — | — | WO | disclosed |
| EP-1509515-A4 | SUBSTITUTED 4-ARYL-4H-PYRROLO 2,3-H CHROMENES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA INC (US) | 2006-07-05 | — | — | EP | disclosed |
| EP-1509515-A2 | SUBSTITUTED 4-ARYL-4H-PYRROLO 2,3-H CHROMENES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | Cytovia, Inc. (US) | 2005-03-02 | — | — | EP | disclosed |
| WO-2003097806-A2 | SUBSTITUTED 4-ARYL-4H-PYRROLO[2,3-H]CHROMENES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA, INC. (US) | 2003-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230140635-A1 | 3-(2-(Aminoethyl)-Indol-4-ol Derivatives, Methods of Preparation Thereof, and the Use as 5-HT2 Receptor Modulators | HTR2C, HTR2A, HTR2B | HTR2A 2/4885HTR1D 16/4885HTR1A 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.